# Maze Therapeutics, Inc.: overview MAZE · Nasdaq · CIK 1842295 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/maze.md) · [Financials](/companies/maze/financials.md) · [Filings](/companies/maze/filings.md) · [Insiders](/companies/maze/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-344903.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-344903). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.5](/filings/0001193125-25-269689.md) | [0.0 d](/filings/0001193125-26-122778.md) | not reported | [0.0](/filings/0000950170-25-107306.md) | not reported | not reported | [20.0](/filings/0001193125-26-219430.md) | [0.0 d](/filings/0001193125-26-344903.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(969.2%)](/filings/0001193125-25-269689.md) | not reported | not reported | not reported | not reported | not reported | [(132.8%)](/filings/0001193125-26-219430.md) | not reported | | Net margin | % | [(990.1%)](/filings/0001193125-25-269689.md) | not reported | not reported | not reported | not reported | not reported | [(121.0%)](/filings/0001193125-26-344903.md) | not reported | | Diluted EPS | $ per share | [(10.25)](/filings/0001193125-25-269689.md) | not reported | [(1.15)](/filings/0001193125-26-219430.md) | [(0.77)](/filings/0001193125-26-344903.md) | [(0.66)](/filings/0001193125-25-269689.md) | not reported | [(0.45)](/filings/0001193125-26-219430.md) | [(0.76)](/filings/0001193125-26-344903.md) | | Free cash flow | $m | [(23.3) d](/filings/0001193125-25-269689.md) | [(23.1) d](/filings/0001193125-26-122778.md) | [(29.8)](/filings/0001193125-26-219430.md) | [(30.4) d](/filings/0001193125-26-344903.md) | [(24.7) d](/filings/0001193125-25-269689.md) | [(27.8) d](/filings/0001193125-26-122778.md) | [(39.2)](/filings/0001193125-26-219430.md) | [(15.2) d](/filings/0001193125-26-344903.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | [168](/filings/0001193125-26-122778.md) | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | [34.4%](/filings/0001193125-26-122778.md) | not reported | | Net margin | % | [31.2%](/filings/0001193125-26-122778.md) | not reported | | Diluted EPS | $ per share | [1.25](/filings/0001193125-26-122778.md) | [(3.05)](/filings/0001193125-26-122778.md) | | Free cash flow | $m | [74.8](/filings/0001193125-26-122778.md) | [(113)](/filings/0001193125-26-122778.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/maze/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $150.2m | 5,032,915 | | Added +465,641 | | [TRV GP IV, LLC](/funds/1688325.md) | 2026-06-30 | $133.5m | 4,473,958 | | Unchanged | | [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $123.0m | 4,120,053 | | Unchanged | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $111.4m | 3,732,569 | | Added +255,007 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $104.5m | 3,502,841 | | Added +932,416 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $101.8m | 3,408,045 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $85.3m | 2,858,876 | | Not compared | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $57.7m | 1,935,000 | | Added +700,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $53.1m | 1,778,222 | | Added +342,566 | | [a16z Capital Management, L.L.C.](/funds/1540358.md) | 2026-06-30 | $50.8m | 1,702,225 | | Unchanged | ## Recent filings [All 219 filings](/companies/maze/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 16:05 ET | [8-K](/filings/0001193125-26-424067.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-424067 | | 2026-08-17 | 16:16 ET | [8-K](/filings/0001193125-26-354092.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-354092 | | 2026-08-11 | 16:48 ET | [10-Q](/filings/0001193125-26-344903.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344903 | | 2026-08-11 | 16:45 ET | [8-K](/filings/0001193125-26-344878.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344878 | | 2026-06-10 | 16:15 ET | [8-K](/filings/0001193125-26-265858.md) | 5.07 Shareholder vote results | 0001193125-26-265858 | | 2026-05-22 | 17:24 ET | [8-K](/filings/0001193125-26-237199.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-237199 | | 2026-05-12 | 16:11 ET | [10-Q](/filings/0001193125-26-219430.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219430 | | 2026-05-12 | 16:07 ET | [8-K](/filings/0001193125-26-219398.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219398 | | 2026-04-28 | 16:30 ET | [DEF 14A](/filings/0001140361-26-017463.md) | Proxy statement, period 2026-06-08 | 0001140361-26-017463 | | 2026-04-22 | 16:56 ET | [8-K](/filings/0001193125-26-170701.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-170701 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-122778.md), filed Mar 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d5c38a3e-ffab-42f6-95fc-02459cd100e9) ## About the filer - CIK: 1842295 - Tickers: MAZE - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:22 ET. No prices; not investment advice.